GRCL
Gracell Biotechnologies Inc.
Chinese clinical-stage biopharmaceutical company developing innovative cell therapies for cancer and autoimmune diseases, based in Suzhou, China with operations in US and China
ADRUnderlying: GRCLCUSIP: 38406L103HealthcareCN1 holder
American Depositary Shares representing Class A ordinary shares — Acquired by AstraZeneca in February 2024, delisted from Nasdaq